Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas

Anti-angiogenic therapy in glioblastoma (GBM) has unfortunately not led to the anticipated improvement in patient prognosis. We here describe how human GBM adapts to bevacizumab treatment at the metabolic level. By performing (13)C(6)-glucose metabolic flux analysis, we show for the first time that...

Descripción completa

Detalles Bibliográficos
Autores principales: Fack, Fred, Espedal, Heidi, Keunen, Olivier, Golebiewska, Anna, Obad, Nina, Harter, Patrick N., Mittelbronn, Michel, Bähr, Oliver, Weyerbrock, Astrid, Stuhr, Linda, Miletic, Hrvoje, Sakariassen, Per Ø., Stieber, Daniel, Rygh, Cecilie B., Lund-Johansen, Morten, Zheng, Liang, Gottlieb, Eyal, Niclou, Simone P., Bjerkvig, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282692/
https://www.ncbi.nlm.nih.gov/pubmed/25322816
http://dx.doi.org/10.1007/s00401-014-1352-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282692/
https://www.ncbi.nlm.nih.gov/pubmed/25322816
http://dx.doi.org/10.1007/s00401-014-1352-5

Ejemplares similares